We have previously shown that the breast cancer susceptibility gene, BRCA1, can transcriptionally activate the p27 Kip1 promoter. The BRCA1-responsive element was defined as a 35 bp region from position À545 to À511. We next determined that within this region is also a potential binding site for the transcription factor Forkhead box (FOX)A1. RNA and protein analysis as well as immunohistochemistry showed that expression of FOXA1 correlated with the expression of the estrogen receptor in a panel of breast cancer cell lines and tissues. In transient transfection reporter assays, FOXA1 could activate the p27 Kip1 promoter. Cotransfection of BRCA1 and FOXA1 resulted in a synergistic activation of the p27 Kip1 promoter. Mutation of the FOXA1 DNA-binding site in the p27 Kip1 promoter-luciferase construct significantly diminished the activity of FOXA1 alone or in combination with BRCA1. Cotransfection of FOXA1 and BRCA1 resulted in a greater amount of each protein compared to transfection of each expression vector alone. The half-life of FOXA1 was increased when coexpressed with BRCA1. Electrophoretic mobility shift assay analysis demonstrated that FOXA1 could bind to a wild-type oligonucleotide containing the FOXA1 binding site in the p27 Kip1 promoter, but this binding was lost upon mutation of this FOXA1 binding site. The protein-DNA binding complex could be supershifted with an antibody directed against FOXA1. The activity of the p27 Kip1 promoter as well as FOXA1 expression was reduced in cells treated with BRCA1 siRNA, thus silencing the expression of BRCA1 protein. In summary, we identified a FOXA1 binding site within the BRCA1-responsive element of the p27
Introduction
The breast cancer susceptibility gene BRCA1 is a tumor suppressor gene that is mutated frequently in hereditary breast cancers. The BRCA1 protein has been assigned a number of different functions, including DNA repair, cell cycle regulation and as a transcription factor. Previously, we have shown that BRCA1 could transcriptionally regulate the cyclin-dependent kinase inhibitor p27 Kip1 , suggesting that this might be a mechanism for the regulation of the cell cycle by BRCA1 (Williamson et al., 2002) .
Our previous study determined that the BRCA1-responsive element of the p27 Kip1 promoter was localized to a 35 bp region at positions À545 to À511 (Williamson et al., 2002) . BRCA1 has been shown to interact with a wide variety of proteins, but we were unable to show that any of these were involved with BRCA1's regulation of p27
Kip1 (Williamson et al., 2002) . Therefore, we further analysed the DNA sequence of the 35 bp BRCA1-responsive element of the p27
Kip1 promoter. Computer analysis using a number of transcription factor databases suggested that the BRCA1-responsive element contained a potential binding site for the transcription factor Forkhead box (FOX)A1 (formerly hepatocyte nuclear factor-3a).
The FOX family of transcription factors contains more than 50 members, which all share homology in their winged-helix DNA-binding domain (Kaestner et al., 2000) . Members of this family have been shown to play roles in cell proliferation, differentiation and metabolic homeostasis (Kaufmann and Knochel, 1996; Zaret, 1999; Kaestner et al., 2000; Costa et al., 2001) .
The FOXA proteins are a group of endoderm-related developmental factors (Zaret, 1999; Kaestner et al., 2000) . In mice, FOXA2 is the first to be expressed in the endoderm progenitor during gastrulation, immediately followed by FOXA1 before organogenesis, and finally, FOXA3 is expressed (Sasaki and Hogan, 1993; Zaret, 1999) . The targeted null mutation of FOXA1 leads to mice that die very soon after birth due to pancreatic defects, whereas the loss of FOXA2 is embryonically lethal due to the absence of endodermal progenitor cells (Weinstein et al., 1994; Kaestner et al., 1999) .
The FOXA1 and FOXA2 proteins share 93% homology in the winged-helix domain, bind similar target sequences and potentially regulate the transcription of numerous genes critical for liver function (Lai et al., 1991; Overdier et al., 1994) . X-ray crystallography has determined that the structure of the FOXA FH domain resembles the globular domain of linker histone H1 (Clark et al., 1993) . In vitro nucleosome assembly experiments further showed that FOXA1 was able to open compacted chromatin by displacing linker histone in an ATP-independent manner (Cirillo et al., 1998 (Cirillo et al., , 2002 . This was the result of high-affinity binding to DNA as well as attachment of the C-terminus of FOXA1 to histones H3 and H4. FOXA1 has also been shown to induce chromatin modifications on several genes including the albumin, estrogen receptor (ER) and a-fetoprotein genes (Cirillo et al., 1998; Shim et al., 1998; Crowe et al., 1999; Robyr et al., 2000) .
Both FOXA1 and FOXA2 proteins are phosphorylated in HepG2 cells. However, the role of phosphorylation with respect to nuclear localization or transcriptional activity for FOXA1 has yet to be determined. FOXA2 has been shown to be phosphorylated by Akt in response to insulin (Wolfrum et al., 2003) . This phosphorylation resulted in the inhibition of FOXA2-mediated transcription due to the cytoplasmic localization of this phosphorylated protein.
Since the BRCA1-responsive element identified in the p27
Kip1 promoter contained a potential FOXA1 DNAbinding site, we examined the expression of FOXA1 in breast cancer cell lines, and further examined the role of FOXA1 in conjunction with BRCA1 on the regulation of the cyclin-dependent kinase inhibitor p27 Kip1 .
Results

BRCA1-responsive element in p27
Kip1 promoter In a previous study, we determined that BRCA1 could transcriptionally regulate the p27 Kip1 promoter (Williamson et al., 2002) . The BRCA1-responsive element was localized to a 35 bp region at position À545 to À511 of the p27 Kip1 promoter (Figure 1a) . We, therefore, examined the sequence of this 35 bp region of the p27
Kip1 promoter to determine whether any DNA motifs were present that corresponded to known binding sites for transcription factors. Analysis using a number of transcription factor databases suggested that the region À544 to À536 corresponded to a binding site for the transcription factor FOXA1, a member of the forkhead family of transcription factors (Figure 1b) .
Expression of FOXA1 in breast cancer RNA was isolated from eight breast cancer cell lines and real-time quantitative PCR was used to determine the expression of FOXA1 mRNA. Variable expression of FOXA1 was found in these breast cancer cell lines. Since a previous study had suggested that FOXA1 expression correlated with ER positivity in breast cancer, we identified the ER status of the cell lines examined here (West et al., 2001) . Of these eight, four are ER þ (BT474, MCF7, T-47D, ZR-75-1) and four are ERÀ (BT20, MDA-MB-231, MDA-MD-468, SKBr3). A comparison of FOXA1 expression between ER þ versus ERÀ breast cancer cell lines indicated that FOXA1 mRNA expression was four times greater in the ER þ breast cancer cell lines compared to the ERÀ breast cancer cell lines (Figure 2A ). Therefore, FOXA1 mRNA expression appears to correlate with ER expression in breast cancer cell lines. However, when we analysed a series of breast tumors for the expression of FOXA1, the difference between ER þ and ERÀ was not as dramatic (data not shown), possibly due to the presence of contaminating normal breast tissue. Expression of FOXA1 RNA was similar between normal breast tissue and breast tumor samples ( Figure 2A) .
Next, we investigated the expression of FOXA1 protein in breast cancer cell lines. Nuclear lysates were immunoblotted for FOXA1 and demonstrated high expression of this protein in the ER þ cell lines MCF7, T-47D, ZR-75-1 and BT474 and very low expression in ERÀ breast cancer cell lines MDA-MB-231 and BT20 ( Figure 2B , data not shown). Thus, FOXA1 protein expression also correlates with ER expression in these breast cancer cell lines.
Furthermore, we analysed a number of breast tumor patient samples for the expression of FOXA1 by immunohistochemistry ( Figure 2C ). This demonstrated that FOXA1 protein is indeed a nuclear protein in breast tissue. Of the 27 ER þ tumors, 74% (20/27) showed very strong expression of FOXA1 protein ( Figure 2C (b) ). Of the six ERÀ tumors, 83% (5/6) showed weak expression of FOXA1 protein ( Figure 2C (c)). Therefore, this confirms the association observed by other studies that FOXA1 expression correlates with ER positivity. FOXA1 is expressed in normal breast tissue, and the expression appears to increase in the ER þ breast tumor tissue ( Figure 2C, a versus b) .
Since FOXA1 is a member of a family of transcription factors that can bind to similar DNA sequences and are expressed coordinately in most cell lines previously studied, we analysed the expression of FOXA2 by RT-PCR. However, we were unable to detect FOXA2 Kip1 promoter. The highlighted region corresponds to position À544 to À536 and is identified as a potential FOXA1 binding site.
BRCA1 and FOXA1 proteins coregulate p27
Kip1 mRNA expression in any of the breast cancer cell lines, or in any breast tumor samples (data not shown).
FOXA1 activates the p27
Kip1 promoter Although FOXA1 protein is expressed in these breast cancer cell lines, we wanted to determine whether it could act upon the p27 Kip1 promoter. Therefore, transient transfection reporter assays were carried out using FOXA1 and BRCA1 alone and in combination to assess the activity of these two proteins on the p27 Kip1 promoter. In these assays, BRCA1 alone activated the p27
Kip1 promoter by 12-14-fold, as we have shown previously ( Figure 3a , Williamson et al., 2002) . In the same assay, FOXA1 alone activated the p27
Kip1 promoter up to 75-fold, and a combination of FOXA1 and BRCA1 appeared to be synergistic in activating the p27 Kip1 promoter (Figure 3a ). Since we had identified a potential FOXA1 binding site at the 5 0 -end of the putative BRCA1-responsive element, we mutated this sequence in the p27 Kip1 promoter decreased the activation of BRCA1 alone by only 20% (Figure 3b ). However, a dramatic decrease occurred in activation by FOXA1 either alone or in combination with BRCA1 ( Figure 3b ). In both instances, the activity on the p27 Kip1 promoter was decreased by 50-75% (Figure 3b ). Therefore, these results suggest that FOXA1 can strongly activate the p27
Kip1 promoter, and this activity is increased dramatically in the presence of BRCA1. Furthermore, mutation of the potential FOXA1 binding site significantly reduces this activity.
We have previously shown that mutant forms of BRCA1 cannot transactivate the p27
Kip1 promoter. Thus, we examined whether mutant forms of BRCA1 could synergize with FOXA1 on the p27 Kip1 promoter. Transient transfection reporter assays were carried out using FOXA1 and various mutant BRCA1 constructs. We used the synthetic mutants BRCA1del500-1843, which is cytoplasmic, BRCA1del515-1091, which has lost the RAD51 binding domains but is still transcriptionally active, and a tumor-derived BRCA1 point mutation (BRCA1 Gln1756insC). In this case, only wild-type BRCA1 and BRCA1del515-1091 were able to synergize with FOXA1 on the p27
Kip1 promoter (Figure 3c ). Therefore, FOXA1 and BRCA1 can act together only when the BRCA1 is localized to the nucleus and has an intact C-terminal transactivation domain.
Next, we used real-time quantitative PCR to show upregulation of endogenous p27
Kip1 transcription by BRCA1 and FOXA1 either alone or in combination ( Figure 3d ). We demonstrated that either BRCA1 or FOXA1 alone can increase endogenous p27 Kip1 expression, with FOXA1 being the most potent. These increases compared to the control are statistically significant to Po0.0001. The combination of BRCA1 and FOXA1 also increases p27 Kip1 transcription, although it is only marginally greater than FOXA1 alone, unlike the effect seen with the combination on the p27 Kip1 promoter-luciferase reporter construct (Figure 3d ).
FOXA1 binds to the p27
Kip1 promoter In order to show that FOXA1 can indeed bind the p27 Kip1 promoter, electrophoretic mobility shift assay (EMSA) analysis was carried out utilizing nuclear extracts from a number of cell lines, along with the 35 bp oligonucleotide identified in our previous study as being the BRCA1-responsive element of the p27 Kip1 promoter (Figure 1b ). We observed a protein-DNA complex only in those extracts that we had previously determined expressed FOXA1 protein (data not shown). We also generated an oligonucleotide with the FOXA1 site mutated identically to the mutation created in the p27
Kip1 promoter-luciferase construct. EMSA analysis using MCF7 extract demonstrated a band with the wild-type oligonucleotide, which was competed away by 100-fold excess cold wild-type oligonucleotide (Figure 4 , lanes 1 and 5). However, no competition was observed with the cold mutant oligonucleotide or a cold oligonucleotide from an unrelated sequence (Figure 4 , lanes 1 and 6-10). Indeed, no binding of MCF7 extract occurred to the mutated oligonucleotide ( Figure 4 , lane 2). Further confirmation that FOXA1 was present in this complex came when a FOXA1 antibody was included in the binding reaction, causing a supershift Kip1 -774 promoter-luciferase construct was used in these assays since this construct was previously shown to have the greatest induction of activity by BRCA1 (Williamson et al., 2002) . Lysates were harvested 48 h post-transfection. The results shown here represent the results from five independent experiments. Results are expressed as RLU, which is the ratio of the firefly luciferase of the promoter-reporter construct compared to the Renilla luciferase used as the control for transfection efficiency. (b) The same promoter sequences as above were tested, except the potential FOXA1 binding site in the p27
Kip1 promoter was mutated, placed in the reporter vector and transient transfection reporter assays were repeated as described above. Results represent five independent experiments. (c) Transient transfection reporter assays were repeated using FOXA1 in combination with wild-type and mutant BRCA1 and BRCA2 for activation of the p27 Kip1 promoter. Results are expressed as RLU, which is the ratio of the firefly luciferase of the promoter-reporter construct compared to the Renilla luciferase used as the control for transfection efficiency. (d) Real-time quantitative PCR was carried out using p27-specific primers. Equal loading was determined using 18S-specific primers. Data are shown as mean7s. (Figure 4, lane 11) . Therefore, these results show that FOXA1 is capable of binding an element in the p27
Kip1 promoter and directly activating this promoter.
FOXA1 protein expression is enhanced by coexpression with BRCA1
Analysis of the nuclear extracts from transiently transfected cells showed that when FOXA1 was cotransfected with BRCA1, greater expression of FOXA1 protein occurred compared to cells transfected with FOXA1 alone (Figure 5a ). We observed this in both HCT116 colon cancer cells and MDA-MB-231 breast cancer cells (Figure 5a and b) . This suggested that BRCA1 might be stabilizing FOXA1 protein.
Since our transient transfection experiments suggested that mutant BRCA1 could not act in concert with FOXA1 to activate the p27 Kip1 promoter, we investigated whether expression of FOXA1 protein was enhanced in HCT116 cells transiently transfected with FOXA1 and BRCA1 (wild-type and mutant). We observed that increased expression of FOXA1 protein occurred only when coexpressed with either wild-type BRCA1 or a mutant BRCA1 capable of transactivating the p27
Kip1 promoter (Figure 5c ). Therefore, we performed experiments to address whether BRCA1 expression could stabilize FOXA1 protein expression. We transiently transfected HCT116 with the FOXA1 expression plasmid either alone or in combination with the BRCA1 expression plasmid, added cycloheximide and harvested the nuclear proteins at intervals over a 24 h period. These nuclear protein lysates were monitored for FOXA1 protein expression by Western immunoblotting with a FOXA1 antibody (Figure 6a, b) . We determined that in cells transiently transfected with FOXA1 alone, the half-life of the FOXA1 protein was approximately 8 h (Figure 6a ). By comparison, the half-life of the FOXA1 protein cotransfected with BRCA1 was greater than 24 h (Figure 6b and c) . Therefore, these results suggest that expression of BRCA1 may indeed stabilize the FOXA1 protein.
Silencing of BRCA1 by siRNA MCF7 cells were transfected with a BRCA1-directed siRNA in combination with the p27 Kip1 promoterluciferase construct. As can be seen, MCF7 cells transfected with increasing amounts of the BRCA1-directed siRNA showed decreasing activity of the p27 Figure 4 FOXA1 protein binds to the potential DNA binding site in the p27 Kip1 promoter. EMSA analysis using nuclear protein extracts from the MCF7 breast cancer cell line and the following oligonucleotides: p27
Kip1 promoter 545-511 wild-type (lanes 1 and 3-5), p27
Kip1 promoter 545-511 mutant (544-536) (lanes 2 and 6-8) and an unrelated DNA sequence (lanes 9 and 10). The mutation of the FOXA1 site in the oligonucleotide was identical to the mutation made at this site in the p27
Kip1 promoter-luciferase reporter construct. The protein-DNA complex observed with the MCF7 nuclear protein extracts could be supershifted by the inclusion of an antibody directed against FOXA1 in the binding reaction (lane 11).
BRCA1 and FOXA1 proteins coregulate p27
Kip1 promoter-luciferase construct (Figure 7a ). Thus, BRCA1 does indeed regulate p27 Kip1 . We also analysed protein extracts from these siRNA-transfected MCF7 cells and demonstrate that the reduction of BRCA1 protein expression is accompanied by a decrease in FOXA1 protein expression (Figure 7b and c) . Therefore, this further suggests that the protein levels of BRCA1 can affect the protein levels of FOXA1.
Discussion
BRCA1 has been shown previously to interact with a number of different proteins, including but not limited to ATF1, p53, Myc, STAT1 and the CBP-interacting protein CtIP (Ouchi et al., 1998 (Ouchi et al., , 2000 Wang et al., 1998; Yu et al., 1998; Zhang et al., 1998; Houvras et al., 2000) . However, in a previous study describing the regulation of the cyclin-dependent kinase inhibitor p27
Kip1 by BRCA1, we determined that none of the already identified partners of BRCA1 were involved with this function (Williamson et al., 2002) . It seemed unlikely given the complexity of the protein that BRCA1 would be acting alone in the regulation of p27
Kip1
. Subsequently, we determined that the 35 bp region of the p27 Kip1 promoter that was responsible for BRCA1 regulation contained a sequence known to bind a liverspecific transcription factor FOXA1. Conflicting data exist as to whether BRCA1 can bind DNA in a sequence-specific manner. However, a study using the CASTing technique determined that BRCA1 protein complexes could bind DNA in a sequencespecific manner and identified an 8 bp recognition motif -TTC(G/T)GTTG (Cable et al., 2003) . This is very similar to the sequence for a FOXA1 binding site.
Other Forkhead transcription factors have been shown to regulate p27
Kip1 in a number of tissues including breast and ovarian tissues (Medema et al., 2000; Castrillon et al., 2003; Cunningham et al., 2004; Jin et al., 2004) . These are members of the FOXO family of Forkhead transcription factors, namely AFX (FOXO4), FKHR (FOXO1) and FKHR-L1 (FOXO3a). We analysed our breast cancer cell lines for expression 
BRCA1 and FOXA1 proteins coregulate p27
Kip1 of these proteins and found that they were either absent or poorly expressed, and the level of expression did not correlate with levels of p27 Kip1 (data not shown). Thus, we focused our attention on FOXA1.
Although FOXA1 has been shown to be important for liver and lung development, very little is known about its expression in breast tissue. Microarray analysis of breast tumor samples suggested that FOXA1 is expressed only in ER þ breast tumors and is reduced significantly in ERÀ breast tumors (West et al., 2001; van't Veer et al., 2002) . We determined that FOXA1 expression did indeed correlate with ER positivity in breast cancer cell lines. Interestingly, FOXA1 could upregulate p27
Kip1 alone to a greater extent than BRCA1 alone, and these two proteins could act in concert upon the p27 Kip1 promoter and on endogenous p27 transcription. This appeared to be due to BRCA1 stabilizing the FOXA1 protein, increasing the half-life of this protein. This stabilizing effect of BRCA1 has also been observed for another of the interacting partners of BRCA1, namely BARD1 (Xia et al., 2003) . Indeed, decreasing the protein expression of BRCA1 also decreased the expression of FOXA1 protein.
Thus, we hypothesized that BRCA1 and FOXA1 proteins might interact in vivo to regulate the expression of p27 Kip1 . Since the effect on protein stability is observed only with a BRCA1 protein having an intact C-terminal BRCT repeat domain, we suggest that the interaction occurs at or near the C-terminus of BRCA1. As a comparison, BARD1 and BRCA1 interact via their N-terminal RING domains, and this interaction and the effect on protein stability is unaffected by C-terminal mutations of BRCA1 (Xia et al., 2003) . Indeed, a study has demonstrated that FOXA1 is decreased in BRCA1-mutated breast cancers (van't Veer et al., 2002) .
A number of studies have examined the expression of p27 Kip1 in various tumor types to determine if there is any diagnostic or prognostic significance. The p27 Kip1 protein expression is decreased in a number of tumor types, including breast, colon, prostate and ovarian tumors (Catzevalos et al., 1997; Ciaparrone et al., 1998; Cordon-Cardo et al., 1998; Masciullo et al., 1999) . Conversely in BRCA1 knockout mouse models, reduction of BRCA1 is accompanied by an increase in the expression of p27
Kip1 at the mRNA and protein levels (Brodie et al., 2001; Deans et al., 2004) . However, in the conditional BRCA1 knockout model, other cell cycle proteins were also upregulated (Brodie et al., 2001) . Another recent study showed that using shRNA to decrease BRCA1 expression in MCF7 resulted in an increase in p27
Kip1 mRNA and transfection of the HCC1937 with wild-type BRCA1 resulted in a decrease in p27
Kip1 (Deans et al., 2004) . This report is at variance with our findings in this and our previous study (Williamson et al., 2002) . The reason for this is not clear, may reflect differences in the experimental procedures. Also, mutant BRCA1 can interfere with the function of wild-type BRCA1, which may explain the unexpected result from the HCC1937 cells (Fan et al., 2001; Deans et al., 2004) . However, our results are in keeping with the studies from breast tumor analysis where mutated or absent BRCA1 is associated with low p27 Kip1 expression. In summary, we have identified FOXA1 as a potential interacting partner for BRCA1, by which both can regulate the expression of p27
Kip1 alone or in concert with BRCA1, and that BRCA1 stabilizes FOXA1 protein.
Materials and methods
Plasmids
The promoter region of p27 Kip1 -774 was generated by PCR and subcloned into pGL2-basic as described previously (Williamson et al., 2002) . The pCR3 expression vectors encoding wild-type BRCA1 and the synthetic and tumorassociated mutants of BRCA1 were constructed as described previously and provided by B Weber (Somasundaram et al., 1997 ). An expression vector for mammalian FOXA1, pRB-FOXA1, was generated and provided by K Zaret (Jackson et al., 1993) .
Cells, transfections and luciferase assays All cell lines were obtained from ATCC. HCT116 colon cancer cells were transfected using 1 mg of each expression plasmid by GenePorter according to the manufacturer's instructions (Gene Therapy Systems). Lysates were harvested 48 h posttransfection, and luciferase assays were carried out according to the manufacturer's instructions (Promega). Transfection efficiency was normalized using pRL-SV40 at 1 10 th of the total DNA concentration.
Western blot analysis Cells were lysed for total protein extraction in a buffer containing 20 mM Tris-Cl, pH 8, 137 mM NaCl, 10% glycerol, 1% Triton X-100, 2 mM EDTA, 1 mM Na 3 VO 4 and protease inhibitors. Nuclear protein extracts were prepared as described previously (Verbeek et al., 1999) . Total and nuclear protein lysates were separated on polyacrylamide gels, transferred to PVDF membranes and then immunoblotted with the following antibodies: anti-C-terminal BRCA1, 1:200 (Santa Cruz); antip27 Kip1 , 1:2500 (Transduction Labs); and anti-FOXA1, 1:1000 (Santa Cruz). Results were visualized by enhanced chemiluminescence (Pierce).
Real-time quantitative PCR Total RNA was prepared from breast cancer cell lines using the RNeasy kit according to the manufacturer's instructions (Qiagen). Total RNA (2.5 mg) was reverse transcribed using random hexamers and Superscript II. The final reaction was diluted five-fold and 5 ml used in the subsequent real-time quantitative PCR employing p27 Kip1 -specific primers and SYBR green. The p27 Kip1 -specific primers are: 5 0 -GTGGACCC AAACACTGATCC and 5 0 -AGAAGAATCGTCGGTTGC AG. Equal loading was determined using primers specific for 18S.
Immunohistochemistry
Paraffin sections from 27 ER þ and six ERÀ breast tumor cancer samples were prepared and analysed with an antibody directed at the C-terminus of FOXA1 at a dilution of 1:500. The sections were then reacted with a biotinylated secondary antibody (1:100 dilution) followed by an HRP-conjugated avidin-biotin complex. HRP-conjugated antibody was also used at a dilution of 1:500. Samples were assessed by light microscopy for intensity of FOXA1 expression in these samples.
FOXA1 protein stability HCT116 cells were transiently transfected with 1 mg of the FOXA1 expression plasmid either alone or in combination with an equal amount of pCR3-BRCA1. At 24 h posttransfection, 10 mg cycloheximide was added to the cells, which were then harvested at various time points after the addition. Nuclear proteins were extracted from these cells, separated on polyacrylamide gels, transferred to PVDF and immunoblotted with an antibody against FOXA1, as described earlier.
Electrophoretic mobility shift assay Double-stranded consensus wild-type or mutant oligonucleotides covering the 35 bp region À545 to À511 of the p27 Kip1 promoter were end-labeled with [g-32 P]ATP by T4 polynucleotide kinase. In all, 10 mg of nuclear protein extract was incubated with 20 000 c.p.m. of labeled oligonucleotide, in the presence of 1.5 mg polydIdC and 4.5 mg bovine serum albumin in a 20 ml volume. Competing cold oligonucleotides at 100-fold molar excess or antibodies (1 mg) were added where indicated. Electrophoresis was performed on a 4% polyacrylamide gel at 34 mA for 2-3 h. The gel was dried and the results visualized by autoradiography.
Co-immunoprecipitation of FOXA1 and BRCA1
Nuclear protein lysates were prepared at a concentration of 1 mg/ml from MCF7 and T-47D breast cancer cell lines. These lysates were incubated with 1 mg of a BRCA1 antibody (C-20; Santa Cruz). The immunoprecipitated proteins were collected using protein A/protein G agarose beads (Calbiochem), washed and resuspended in Laemmli sample buffer (Biorad). The boiled samples were separated by SDS-PAGE, transferred to PVDF membrane (Millipore) and probed with an antibody for FOXA1 (Santa Cruz). Results were detected by enhanced chemiluminescence (Pierce).
Silencing of BRCA1 protein expression BRCA1-directed siRNA and a control siRNA were purchased from Dharmacon Co. (Ganesan et al., 2002) . MCF7 cells were transfected with the BRCA1-directed or control siRNA, in the presence or absence of the p27
Kip1 promoter reporter-luciferase construct, using Lipofectamine 2000, according to the manufacturer's instructions (Invitrogen). At 48 h post-transfection, cell lysates were prepared for either total protein analysis or luciferase assays as described above.
